HIGHLIGHTS
- who: A. Haslam from the Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, USA have published the Article: Design, power, and alpha levels in randomized phase II oncology trials, in the Journal: (JOURNAL)
- what: The authors showed that the most commonly accepted a level (of 0.025) was used in and amp;lt;17% of phase II trials. The authors found that many studies (35%) assumed a onesided a level of >0.5, and only four studies provided justification for using an a level higher than a traditional two-sided 0 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.